-
Product Insights
Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) - Drugs In Development, 2023’, provides an overview of the Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Encephalomyelitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Encephalomyelitis - Drugs In Development, 2023’, provides an overview of the Encephalomyelitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Encephalomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
African Trypanosomiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘African Trypanosomiasis - Drugs In Development, 2023’, provides an overview of the African Trypanosomiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for African Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Fragile X Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Fragile X Syndrome - Drugs In Development, 2023’, provides an overview of the Fragile X Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Trypanosomiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Trypanosomiasis - Drugs In Development, 2023’, provides an overview of the Trypanosomiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Acute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Drugs In Development, 2023’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Autism Spectrum Disorder (ASD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Autism Spectrum Disorder (ASD) - Drugs In Development, 2023’, provides an overview of the Autism Spectrum Disorder (ASD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Autism Spectrum Disorder (ASD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OLX-101A in Hypertrophic Scars
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OLX-101A in Hypertrophic Scars report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OLX-101A in Hypertrophic Scars Drug Details: OLX-101A (BMT-101) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PAX-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry PAX-101 Drug Details Suramin (PAX-101) is under development for the treatment of human African...